AI & Machine Learning

AI firm DreamzTech Solutions gains major recognition, validating its AI-first strategy and signaling a new wave of Indian tech leaders on the global stage.

A brief delay in Avidity's stockholder vote signals the final, complex steps before its acquisition by Novartis and the launch of a new spin-off.

ITF Therapeutics will unveil 10 new data presentations on its Duchenne therapy, DUVYZAT, offering critical new insights on long-term safety and efficacy.

With a $2.5B valuation and new brand, Mews is betting its unified platform can solve hospitality's biggest problems: fragmentation and inefficiency.

A new app aims to reduce the burden on families by centralizing care, medical, and long-term financial plans in one secure platform.

Pure Storage rebrands as Everpure and acquires 1touch, betting its future on providing the intelligent data management layer essential for enterprise AI.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

With stellar trial data and a fast-tracked FDA submission, CG Oncology prepares for a pivotal presentation at the TD Cowen Health Care Conference.

iRegene Therapeutics hits dual milestones, advancing AI-derived cell therapies for Parkinson's in the US and Multiple System Atrophy in China.

January data shows a massive jump in corporate financing requests, hinting at a busy year for investment, while the municipal market tells a different story.

With a new CEO known for commercial turnarounds, oneworld signals a strategic push for tech integration, customer value, and competitive growth.

A landmark FDA approval for Bracco's VUEWAY allows high-quality MRI scans in neonates with half the standard gadolinium dose, easing safety concerns.

A2Z Cust2Mate reports a pivotal quarter with up to $5.2M in Q4 revenue, as the delivery of over 2,000 AI-powered smart carts begins to pay off.

With its lead CAR-T therapy, Descartes-08, in late-stage trials, Cartesian Therapeutics is set to update investors on its pioneering work in autoimmune disease.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

A new initiative offers biotech firms free access to advanced epiproteomic analysis, aiming to accelerate the development of next-generation precision medicines.

A new three-tube collection system from BD promises to improve accuracy, streamline lab work, and enhance patient safety by reducing sample contamination.

A new platform by Dr. Jess Ingrassellino launches to demystify music tech, empowering a new generation of electric string players and their teachers.

New 12- and 24-month data for Benitec Biopharma's BB-301 gene therapy offers renewed hope for patients with a rare, debilitating muscular dystrophy.